Glioblastoma
ORPHA:360DiseaseMultigenic/multifactorial, Not applicableAll ages
Фенотипы (HPO)15
Облигатный (100%)1
HP:0012174Glioblastoma multiforme
Очень частый (80–99%)1
HP:0025461Abnormal cell morphology
Частый (30–79%)11
HP:0012378Fatigue
HP:0012638Abnormality of nervous system physiology
HP:0000572Visual loss
HP:0000712Emotional lability
HP:0001273Abnormal corpus callosum morphology
HP:0001324Muscle weakness
HP:0002181Cerebral edema
HP:0002315Headache
HP:0002463Language impairment
HP:0002500Abnormal cerebral white matter morphology
HP:0003470Paralysis
Периодический (5–29%)2
HP:0001250Seizure
HP:0002354Memory impairment
Эпидемиология7
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Annual incidence | 1-9 / 100 000 | 3 | Worldwide | Value and class |
| Point prevalence | 1-9 / 100 000 | 1 | Worldwide | Value and class |
| Annual incidence | 1-9 / 100 000 | 2.52 | Europe | Value and class |
| Annual incidence | 1-9 / 100 000 | 3.2 | United States | Value and class |
| Annual incidence | 1-9 / 100 000 | 4.2 | Croatia | Value and class |
| Annual incidence | 1-9 / 100 000 | 3.7 | Greece | Value and class |
| Annual incidence | 1-9 / 100 000 | 3 | Specific population | Value and class |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)